RJ Hamster
Med-X is preparing for a possible NASDAQ listing (ticker:…
 You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Med-x Inc. Med-X is preparing for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before global validation changes everything.In independent lab studies, Med-X’s all-natural pesticides have outperformed chemical brands in certain use cases, delivering powerful results without the toxic tradeoffs associated with traditional pest control.Now, Med-X is pursuing a potential milestone that could redefine the industry: becoming the first botanical pesticide ever pre-qualified by the World Health Organization.The global biopesticide market is projected to grow nearly 3x by 2030, expanding from $5.8 billion to $17.6 billion as governments move away from synthetic chemicals. A WHO pre-qualification would position Nature-Cide as a globally recognized solution for public health, agriculture, and mosquito-borne disease control – opening doors that most pesticide companies can’t access.Nature-Cide’s plant-based formulation prioritizes safety while delivering industrial-grade performance, challenging long-held assumptions about what botanical solutions can achieve on a global scale.NASDAQ Ticker: MXRX Reserved!The Real Opportunity to Become a Shareholder Is Now!Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, agricultural, and public-health sectors. Proudly manufactured in the USA, Nature-Cide reflects a commitment to scalable, sustainable innovation.Already sold through eCommerce giants Amazon, Walmart, and Kroger, and expanding into 41 international markets, Med-X is positioning itself for its next major chapter.Simpler. Safer. More Effective Pesticides.Become a Med-X shareholder at $4 per share before their NASDAQ plans unfold.DisclosuresThis is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com  We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.We would like to inform you that this is a paid advertisement for Med-X’s Regulation A+ Offering offering and we have received or expect to receive compensation in connection with the disbursing this communication for Med-X . The compensation could consist of $1,000 or more and was received/will be received from Investing Media Solutions.This communication should not be considered as an endorsement of Med-X and we are not responsible for any errors or omissions in any information provided about by or about Med-X.We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.This disclosure is made as of 01/21/2026.Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today’s Bonus Content: “Big, Beautiful Bill” = the next bull market? |
